9/18/2007 11:33:54 AM
WALTHAM, Mass. & SINGAPORE--(BUSINESS WIRE)--Artisan Pharma, Inc. and A-Bio Pharma Pte Ltd. today jointly announced that they have finalized a strategic and mutually exclusive manufacturing relationship on the process development, scale-up and manufacture of ART-123, a recombinant protein for the treatment of DIC (disseminated intravascular coagulation) in sepsis. A-Bio will undertake the various development and validation activities necessary to ensure further clinical development and commercial supply of ART-123 for Artisan, and, in return, Artisan will enter into a preferential and long term supply agreement with A-Bio. Specific terms of the relationship were not disclosed.
comments powered by